10.45
a.m. – 12.30 p.m. |
SYMPOSIUM SPONSORED BY SANOFI AVENTIS |
|
|
|
Intra-abdominal
adiposity,
metabolic syndrome and
cardiovascular disease
Co-chair
by: G. Alberti
(UK) & P. Zimmet
(Australia) |
|
 |
|
Welcome
and introduction ..........................................................................................................................
G. Alberti (UK) |
|
|
| |
|
The
metabolic syndrome and abdominal
obesity:
from prevalence to future
recommendations ....................................................................................
P. Zimmet (Australia) |
|
|
| |
|
Relationship
between intra-abdominal adiposity,
metabolic disorders & atherosclerosis
.......................................................................................................
P. Libby (USA) |
|
|
| |
|
The
endocannabinoid system: a new
target for multiple cardiometabolic
risk management (emphasizing
peripheral) ......................................................................................
R. Maldonado (Spain) |
|
|
| |
|
CB1-blockade
for the management of cardiometabolic
risk factors in patients
with
intra-abdominal adiposity (results
from RIO-programme pooled data)
..................................
J.-P. Després
(Canada) |
|
|
| |
|
Conclusions/
Questions and answers ..............................................................................................
P. Zimmet (Australia) |
|
|
